Corporate Health AwardCorporate Health Award
Deutschlands renommierteste Auszeichnung und führende Qualitätsinitiative für nachhaltiges Corporate Health Management
Receive Sample Copy of Report@ https://bit.ly/30BwCpz
The global cell and tissue culture supplies market is expected to witness considerable growth during the forecast period on account of advanced applications of cell and tissue culture equipment and consumables in the life science research activities. Moreover, the requisition of optimal environment to conduct cell and tissue related research activities requires customized supplies which increases their demand in the life science industry.
Based on consumable, the cell and tissue culture supplies market is categorized into media, reagent, sera, cryoprotective agents and contamination detection kits. The media category dominated the market during the historical period, mainly due to the increasing demand of customized media for research purposes. The media category is further classified into chemically defined media, classical media, protein-free media, lysogeny broth, serum-free media and specialty media. The reagent category is sub-categorized into protease inhibitors, albumin, thrombin, cytokines and amino acids.
Receive a Free Sample Copy of this Report: https://bit.ly/39Xyrl9
Owing to the soaring geriatric population and the rising prevalence of obesity and diabetes mellitus in several countries, the demand for self-monitoring blood glucose (SMBG) devices is expected to rise in the coming years. As per a report by the United Nations Department of Economic and Social Affairs (UNDESA) on the worldwide ageing population, the population of people aged 60 years and above is increasing at a huge rate. The share of the geriatric population across the globe recorded a huge increase, to 11.7% in 2013 from 9.2% in 1990, and it is predicted to increase to 21.1% by the end of 2050.
The increasing awareness about diabetes and its numerous complications, such as diabetic foot ulcer and delayed wound healing, is another major factor propelling the adoption of SMBG devices across the world. For instance, the International Diabetes Federation (IDF) conducted an event in Hyderabad, India in October, 2018, called ‘IDF Diabetes Complications and Foot Congress’ for increasing the awareness regarding diabetes and its complications and management methods amongst the people of the city.
Receive Free Sample Copy of this Report @ https://bit.ly/2K6PnN8
The wireless technology, especially mobile phones, are increasingly being utilized across the globe. The rising usage of mobile phones has made life easier on a lot of fronts. Communication has become easier, and now with the smart phones, people can almost do everything they can do with their computers via smartphones. In 2020, about 3.5 billion people are using smartphones, which is about 45% of the world’s population owing a smartphone. In addition to this, the total number of people across the globe who own a smart and feature phone is 4.78 billion, which is approximately 61% of the world’s population .
These days mobile phones, and other devices including personal digital assistances and patient monitoring devices, are also being utilized for medical and public health practices, which is also called mHealth. As per the United Nations Food and Drug Administration, about 500 million people around the world were utilizing personal healthcare applications in 2015, which was projected to grow to over 1 billion in 2018 . A major application of mHealth is medication adherence, which is the degree to which the person’s behavior corresponds to the agreed recommendations from healthcare providers. Poor adherence to the prescribed regimens can lead to serious healthcare consequences . Attributed to this, the medication adherence market is projected to witness significant growth in the coming years.
Die Initiatoren EUPD und Handelsblatt sowie die Sonderpreispartner Techniker Krankenkasse, IKK classic, Men's Health/Women's Health und BVMW - Bundesverband mittelständische Wirtschaft e.V. gratulieren den diesjährigen Preisträgern!
Alle Infos unter http://www.ch-award.de
According to a report by P&S Intelligence, the global radiotherapy market is expected to generate a revenue of $17,194.4 million by 2030, increasing from $7,222.4 million in 2019, advancing at an 8.4% CAGR during the forecast period (2020–2030).
The number of cancer cases has been rising all across the globe over the past few years. As per the American Institute of Cancer Research, by 2030, the number of new cancer incidence is expected to reach 25 million. The prevalence of cancer is further predicted to be the highest in low and middle-income countries, including India and China. Cancer is among the most common chronic diseases around the globe, and was responsible for 9.6 million deaths in 2018, as per the World Health Organization.
Receive Sample Copy of this Report: https://www.psmarketresearch.com/market-analysis/radiotherapy-market-revenue/report-sample?utm_medium=Pramod&utm_source=Xing
The prevalence of cancer can be decreased by providing efficient medical care at initial stage of the disease, which can be done by radiotherapy and chemotherapy. Radiotherapy is majorly used for treating cancer, reducing the risk of cancer coming back if a person goes through surgery, and relieving symptoms if the patient cannot be cured. It is considered the most effective treatment for cancer, however, its effectiveness varies from person to person . According to a report by P&S Intelligence, the global radiotherapy market is expected to generate a revenue of $17,194.4 million by 2030, increasing from $7,222.4 million in 2019, advancing at an 8.4% CAGR during the forecast period (2020–2030).
Want to join the discussions?
Log in to read, write and comment on group posts.
Please log in now to view upcoming events.
Der Corporate Health Award ist seit 2009 die renommierteste Auszeichnung in Deutschland für vorbildhaftes Corporate Health Management.
Unternehmen und Organisationen jeder Größe und Branche erhalten kostenfreien Zugang zur Bewerbung sowie zum anschließenden individuellen Deutschland-Benchmark zur Standortbestimmung des eigenen Corporate Health Managements.